A new therapeutic agent for protothecia

Ravuconazole and fosravuconazole compositions provide a novel and effective treatment for protothecosis by targeting Prototheca species, addressing the ineffectiveness of current antifungal agents and enhancing treatment outcomes for protothecosis in animals and humans.

JP7594260B2Active Publication Date: 2024-12-04SEREN PHARMA INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2021530729
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-07-11
Filing Date
2020-07-09
Publication Date
2024-12-04
Estimated Expiration
2040-07-09

AI Technical Summary

Technical Problem

Current antifungal agents, such as amphotericin B and azoles, exhibit weak clinical responses against Prototheca infections, particularly in strains of Prototheca wickerhamii and Prototheca zopfii, making it difficult to treat protothecosis in animals and humans.

Method used

Ravuconazole and its prodrug fosravuconazole are developed as active ingredients in pharmaceutical compositions for treating and preventing protothecosis, demonstrating high sensitivity against Prototheca species, including Prototheca wickerhamii and Prototheca zopfii.

Benefits of technology

Ravuconazole and fosravuconazole show significant antialgal activity, offering a more effective treatment option for protothecosis in animals and humans, including conditions like canine, feline, and bovine mastitis, with improved efficacy compared to existing drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007594260000001
    Figure 0007594260000001
  • Figure 0007594260000002
    Figure 0007594260000002
  • Figure 0007594260000003
    Figure 0007594260000003
Patent Text Reader

Abstract

The purpose of the present invention is to provide a composition that is effective for the treatment of a prototheca disease. The present invention provides a composition characterized by containing ravuconazole as an active ingredient, and being administered to an animal suffering from a prototheca disease caused by Prototheca wickerhamii or Prototheca zopfii.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a novel therapeutic or preventive agent for protothecia. [Background technology]

[0002] Prototheca is a type of algae, but it does not perform photosynthesis because it has secondarily lost its chloroplasts. Therefore, it is a heterotrophic organism that obtains energy from an external source, and obtains nutrition through saprophytic or parasitic means. It inhabits moist environments such as soil, plant surfaces, the digestive tracts of animals (host intestinal flora), lakes and sewage around the world, but it is also a zoonotic pathogen that can infect humans and animals.

[0003] Infections caused by Prototheca are called protothecia, and are a zoonotic disease that can infect dogs, cats, livestock, and humans. Protothecia infections have been attracting attention in recent years as an emerging infectious disease, and multidisciplinary and international cooperation is required for control. In Japan, the first human protothecia was reported in 1983, and has since been reported sporadically.

[0004] Prototheca inhabits plant surfaces, soil, and lakes and marshes, and is therefore thought to be transmitted through the environment, but it is also a pathogen of opportunistic infections, as it is always present in the digestive tract of animals. For this reason, prototheca infections in animals have been reported in various parts of the world, including Japan, from dogs and cats to dairy cows as a causative microorganism of mastitis.

[0005] Protothecia in dogs and cats causes acute to chronic inflammation of the skin, but it is also a fatal disease that disseminates to organs throughout the body, including the central nervous system. In cats, infection is mainly seen in the skin, and the route of infection is often through skin trauma. On the other hand, it is said that dogs often suffer from more severe disseminated (deep) protothecia. Protothecia is also considered an opportunistic infection, and it is thought that the onset of bacterial replacement due to the administration of antibacterial agents for diarrhea and the increase in the frequency of administration of immunosuppressants and anticancer drugs are more likely to cause it. In the case of immunodeficiency, there is also concern that the skin infection may progress to disseminated infection. In addition, protothecia mastitis in cows causes a decrease in milk quality and zoonotic diseases. Thus, protothecia in animals is considered a problem in industrial animals and pets, and there is an urgent need to establish methods to prevent and treat it.

[0006] The best known species responsible for protothecia are Prototheca wickerhamii and Prototheca zopfii. Prototheca wickerhamii is the most common pathogen of humans and small animals, while Prototheca zopfii causes sporadic protothecia in humans and small animals.

[0007] The antifungal drugs amphotericin B (AMB) and azoles have been used to treat this disease, but clinical responses in humans and animals have generally been poor. Our previous studies of in vivo susceptibility to AMB, gentamicin (GM), kanamycin (KM) and itraconazole (ITZ) have shown that these drugs are ineffective against some strains of Prototheca wickerhamii and Prototheca zopfii (Non-Patent Document 1).

[0008] The present inventors have reported the susceptibility of Prototheca bovine mastitis isolates to kanamycin (KM), gentamicin (GM), amphotericin B (AMB), and itraconazole (ITZ) (Non-Patent Document 2). As a result, it has been reported that Genotype 2 of Prototheca zopfii, the causative bacterium of mastitis, has low drug susceptibility, which is one of the reasons why it is difficult to treat mastitis with drugs. [Prior art documents] [Non-patent literature]

[0009] [Non-Patent Document 1] Sobukawa H et al., In vitro susceptibility of Ptototheca zofii genotypes 1 and 2, Med. Mycol. 2011; 49:222-224 [Non-Patent Document 2] Rui Kanou et al., The Journal of Farm Animal in Infectious Disease, Vol.5, No.4, 2016, p139-143 Summary of the Invention [Problem to be solved by the invention]

[0010] An object of the present invention is to provide a novel therapeutic or preventive agent that is effective against infections caused by Prototheca. [Means for solving the problem]

[0011] As a result of intensive research, the present inventors have found that P. putrotheca exhibits high sensitivity to ravuconazole, and have completed the present invention. The present invention includes the following aspects. [1] A composition for treating or preventing protothecia, comprising ravuconazole or a pharma- ceutically acceptable salt, hydrate or solvate thereof as an active ingredient. [2] The composition described in [1] above, which is used for the treatment or prevention of protothecia in dogs or cats. [3] The composition according to [1] above, which is used for the treatment or prevention of protothecia (preferably protothecal bovine mastitis) in cattle. [4] The composition according to [1] above, which is a pharmaceutical composition for treating or preventing protothecia in humans. [5] The composition according to any one of [1] to [4] above, wherein the protothecia is protothecia caused by Prototheca wickerhamii. [6] The composition according to any one of the above [1] to [4], wherein the protothecia is protothecia caused by Prototheca zopfii. [7] A composition for treating or preventing protothecia, comprising as an active ingredient a prodrug of ravuconazole (preferably fosravuconazole), or a pharma- ceutically acceptable salt, hydrate or solvate thereof. [8] The composition according to [7] above, which is used for the treatment or prevention of protothecia in dogs or cats. [9] The composition according to [7] above, which is used for the treatment or prevention of protothecia (preferably protothecal bovine mastitis) in cattle.

[10] The composition according to [7] above, which is a pharmaceutical composition for treating or preventing protothecia in humans.

[11] The composition according to any one of [7] to

[10] above, wherein the protothecia is protothecia caused by Prototheca wickerhamii.

[12] The composition according to any one of the above [7] to

[10] , wherein the protothecia is protothecia caused by Prototheca zopfii.

[0012]

[13] A method for treating protothecia, comprising administering to an animal suffering from protothecia a therapeutically effective amount of ravuconazole, or a pharma- ceutical acceptable salt, hydrate, or solvate thereof.

[14] The method of treatment described in

[13] above, wherein the animal is a dog or a cat.

[15] The method of treatment described in

[13] above, wherein the animal is a cow.

[16] The method of treatment described in

[13] above, wherein the animal is a human.

[17] The method for treating protothecia according to any one of

[13] to

[16] above, wherein the protothecia is caused by Prototheca wickerhamii.

[18] The method for treating protothecia according to any one of the above

[13] to

[16] , wherein the protothecia is caused by Prototheca zopfii.

[19] A method for treating protothecia, comprising administering to an animal suffering from protothecia a therapeutically effective amount of a prodrug of ravuconazole (preferably fosravuconazole), or a pharma- ceutically acceptable salt, hydrate, or solvate thereof.

[20] The method of treatment described in

[19] above, wherein the animal is a dog or a cat.

[21] The method of treatment described in

[19] above, wherein the animal is a cow.

[22] The method of treatment described in

[19] above, wherein the animal is a human.

[23] The method for treating protothecia according to any one of

[19] to

[22] above, wherein the protothecia is caused by Prototheca wickerhamii.

[24] The method for treating protothecia according to any one of

[19] to

[22] above, wherein the protothecia is caused by Prototheca zopfii. Effect of the Invention

[0013] The present invention provides a composition for the effective treatment or prevention of protothecia. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] The present invention will be described below with exemplary embodiments as examples, together with preferred methods and materials that can be used in the practice of the present invention, but the present invention is not limited to the embodiments described below. Unless otherwise specified in the text, all technical and scientific terms used in this specification have the same meaning as commonly understood by those skilled in the art to which the present invention belongs. In addition, any materials and methods equivalent or similar to those described in this specification can be used in the practice of the present invention. In addition, all publications and patents cited in this specification in connection with the invention described in this specification constitute a part of this specification, for example, as showing methods, materials, etc. that can be used in the present invention.

[0015] In this specification, when the expression "X to Y" is used, it is used to mean that X is the lower limit and Y is the upper limit, or that X is the upper limit and Y is the lower limit. As used herein, the term "ravuconazole" in the context of a composition for treatment or prevention or a method for treatment or prevention is intended to include ravuconazole, its pharma- ceutically acceptable salts, hydrates and solvates.Similarly, as used herein, the term "fosravuconazole" is intended to include fosravuconazole, its pharma-ceutically acceptable salts, hydrates and solvates.

[0016] One embodiment of the present invention is a composition (preferably a pharmaceutical composition) comprising ravuconazole as an active ingredient, intended for use in animals suffering from protothecia. Another aspect of the present invention is a composition (preferably a pharmaceutical composition) comprising ravuconazole as an active ingredient, for use in animals suffering from protothecia caused by Prototheca wickerhamii. Another aspect of the present invention is a composition (preferably a pharmaceutical composition) comprising ravuconazole as an active ingredient, for use in animals suffering from protothecia caused by Prototheca zopfii. One embodiment of the present invention is a composition (preferably a pharmaceutical composition) comprising as an active ingredient a prodrug of ravuconazole, preferably fosravuconazole, for use in treating animals suffering from protothecia. Another aspect of the present invention is a composition (preferably a pharmaceutical composition) comprising as an active ingredient a prodrug of ravuconazole, preferably fosravuconazole, for use in treating animals suffering from protothecia caused by Prototheca wickerhamii. Another aspect of the present invention is a composition (preferably a pharmaceutical composition) comprising as an active ingredient a prodrug of ravuconazole, preferably fosravuconazole, for use in treating animals suffering from protothecia caused by Prototheca zopfii.

[0017] Ravuconazole has been reported as a compound that exhibits antibacterial activity against a variety of fungal pathogens, including Candida, Aspergillus, and Cryptococcus. Ravuconazole is an azole antifungal compound having the following structural formula (I):

[0018] [ka] A method for producing ravuconazole is disclosed, for example, in Organic Process Research & Development 2009, 13, 716-728, and the compound can be produced by referring to the disclosure. The disclosure is incorporated herein by reference. In producing the compound, a person skilled in the art can appropriately use techniques known in the art without any restrictions.

[0019] Fosravuconazole is a compound having the following structural formula (II) in which the hydroxyl group of ravuconazole is replaced by phosphomonooxymethyl ester.

[0020] [ka] Fosravuconazole is a prodrug of ravuconazole, and when administered to animals, such as humans, it is rapidly converted to ravuconazole. L-lysine ethanolate of fosravuconazole is currently marketed as a medicine for tinea unguium. Fosravuconazole can also be synthesized by using suitable techniques known in the art.

[0021] The ravuconazole contained in the composition of the present invention may be a pharma- ceutically acceptable salt. The term "pharma-ceutically acceptable salt" refers to any non-toxic salt formed from the compound represented by the above formula (I). Suitable salts include, for example, but are not limited to, inorganic acid salts such as hydrochloride, hydrobromide, hydroiodide, phosphate, hydrogen phosphate, and sulfate; organic acids such as acetate, trifluoroacetate, malate, succinate, tartrate, lactate, citrate, maleate, fumarate, sorbate, ascorbate, salicylate, phthalate, methylsulfonate, trifluoromethylsulfonate, and benzenesulfonate; inorganic salts such as ammonium salts; alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; salts of acidic groups such as carboxylates; salts with organic bases such as lower alkylamines such as methylamine, ethylamine, and cyclohexylamine; and substituted lower alkylamines such as diethanolamine and triethanolamine; and amino acid salts such as glycine, lysine, arginine, ornithine, glutamate, and aspartate.

[0022] The ravuconazole contained in the composition of the present invention may also be a water-containing product such as a hydrate or a solvate formed from the compound represented by formula (I) above. The term "hydrate" as used herein means a compound or a salt thereof further comprising a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces. The term "solvate" as used herein means a compound or a salt thereof further comprising a stoichiometric or non-stoichiometric amount of solvent bound by non-covalent intermolecular forces. Preferred solvents are volatile, non-toxic, and / or trace amounts acceptable for administration to animals, preferably humans. For example, but not limited to, water, ethanol, etc.

[0023] The fosravuconazole contained in the composition of the present invention may be a pharma- ceutically acceptable salt. The term "pharma-ceutically acceptable salt" refers to any non-toxic salt formed from the compound represented by the above formula (II). Specific examples include the above salts described in relation to ravuconazole. The fosravuconazole contained in the composition of the present invention may be a water-containing product such as a hydrate or a solvate formed from the compound represented by the above formula (II). Hydrate and solvate have the same meaning as above. Preferred solvents are volatile, non-toxic, and / or trace amounts acceptable for administration to animals, preferably humans, including, but not limited to, water, ethanol, etc. The fosravuconazole contained as an active ingredient in the composition of the present invention is preferably an L-lysine ethanol adduct of fosravuconazole.

[0024] The composition of the present invention may contain a prodrug of ravuconazole as an active ingredient. The "prodrug" of ravuconazole includes both "prodrug esters" and "prodrug ethers". "Prodrug esters" include esters and carbonates formed by reacting the hydroxyl of the compound represented by formula (I) above with either an alkyl, alkoxy, or aryl substituted acylating or phosphorylating agent to produce acetates, pivalates, methyl carbonates, benzoates, amino acid esters, phosphates, half acid esters (e.g., malonates, succinates, or glutarates), and the like, using methods known to those skilled in the art. The term "prodrug ethers" as used herein includes both phosphate acetals and glucosides of the compound represented by formula above, prepared using methods known to those skilled in the art. Prodrugs refer to compounds that are converted in vivo, for example by hydrolysis in blood, to the parent compound represented by formula (I) above.

[0025] The prodrug of ravuconazole contained in the composition of the present invention may be a pharma- ceutically acceptable salt.The prodrug of ravuconazole contained in the composition of the present invention may also be a water-containing product such as a hydrate or a solvate. The prodrug contained in the composition of the present invention is preferably fosravuconazole, more preferably fosravuconazole-L-lysine ethanolate.

[0026] The compositions of the present invention may include, in addition to a compound, either ravuconazole or a prodrug of ravuconazole, one or more pharma- ceutically acceptable carriers, and, optionally, other medicinal agents, such as antifungal agents.

[0027] As used herein, the term "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coating agents, antioxidants, chelating agents, preservatives (e.g., antimicrobial agents), surfactants, buffers, osmotic pressure adjusting agents, absorption delaying agents, salts, drug stabilizers, excipients, diluents, binders, disintegrants, sweeteners, flavoring agents, lubricants, dyes, and the like, and combinations thereof, as would be known to one of skill in the art. Except insofar as any carrier is incompatible with the active ingredients of the invention, it may be used in the compositions or methods of treatment of the invention.

[0028] The term "therapeutically effective amount" as used herein refers to an amount of ravuconazole or a prodrug of ravuconazole (preferably fosravuconazole) sufficient to produce a therapeutic effect when administered to an animal in need of treatment. The therapeutically effective amount varies depending on the subject animal and the disease condition to be treated, the subject animal's weight and age, the severity of the disease condition, the method of administration, etc., and can be easily determined by one skilled in the art.

[0029] The term subject animal as used herein refers to an animal in need of treatment, typically a mammal, such as a primate (e.g., human), cat, dog, cow, sheep, goat, horse, rabbit, rat, mouse, koala, etc. In certain embodiments, the subject animal is preferably a human, cat, dog, or cow.

[0030] The subject to which the composition of the present invention is administered is an animal suffering from protothecia, preferably an animal suffering from protothecia caused by Prototheca wickerhamii or Prototheca zopfii.

[0031] Compositions of the present invention containing either ravuconazole (formula (I) above) or a prodrug of ravuconazole (e.g., fosravuconazole (formula (II) above)) can be formulated, for example, in accordance with known methods for formulating pharmaceutical compositions. Representative pharmaceutical compositions may contain pharma- ceutically acceptable carriers as described above. The use of these carriers is well known in the art. Additionally, methods for preparing pharmaceutical compositions containing active ingredients are well known in the art.

[0032] The compositions of the present invention may be formulated to suit a particular route of administration depending on the intended use. The routes of administration include, but are not limited to, oral, parenteral, intravenous, intradermal, subcutaneous, transdermal, inhalation, topical, transmucosal, rectal, or ophthalmic administration. The compositions of the present invention may be formulated in solid or liquid form. The solid forms include, but are not limited to, tablets, capsules, pills, granules, powders, suppositories, patches, ointments, creams, and gels. The liquid forms include, but are not limited to, solutions, suspensions, emulsions, lotions, and sprays. The compositions of the present invention are typically administered, but are not limited to, oral, intravenous, intramuscular, or transdermal.

[0033] The compositions of the present invention formulated for oral administration may be either liquid compositions or solid compositions. For liquid formulations, the compositions may be prepared using liquid carriers such as water, glycols, oils, alcohols, and the like. For solid formulations such as tablets and capsules, the compositions may be prepared using solid carriers such as starch, sugar, kaolin, ethyl cellulose, calcium and sodium carbonate, calcium phosphate, talc, lactose, and the like, generally containing binders, disintegrants, and the like, along with lubricants such as calcium stearate. Tablets and capsules are the most advantageous oral dosage forms due to their ease of administration. For ease of administration and uniformity of dosage, it is particularly advantageous to formulate the compositions in unit dosage form. A composition in unit dosage form constitutes one embodiment of the present invention.

[0034] The composition of the present invention can be prepared as, for example, a patch, ointment, or cream for transdermal administration. The patch may be any of, but is not limited to, a tape or a poultice, and can be prepared, for example, by using an acrylic adhesive, a rubber adhesive, or a silicone adhesive as a base material, and blending ravuconazole or a prodrug of ravuconazole as an active ingredient into the base material. In addition, additives used in patches can be added according to conventional methods to stabilize the active ingredient, control the dissolution, and control the adhesiveness. When preparing an ointment or cream, it can be prepared according to conventional methods using a hydrophobic base (e.g., petrolatum) or a hydrophilic base (e.g., an emulsifier or polyethylene glycol). In addition, various additives used in the technical field can be added. In addition, the composition of the present invention can be used in any dosage form, such as a gel, a liquid, a suspension, or a spray, and preparation into these dosage forms can be performed using materials and methods used in the technical field.

[0035] The composition of the present invention can be prepared, for example, as eye drops for administration by instillation into the eye. The eye drops may be in any form, such as aqueous eye drops, suspension eye drops, oily eye drops, eye ointments, or eye drops that are dissolved when used, and these forms can be prepared using materials and methods used in the art.

[0036] The compositions of the present invention can be prepared for injection and can take the form of suspensions, solutions or emulsions in oily or aqueous vehicles such as 0.85% sodium chloride in water or 5% dextrose. They can also contain formulatory agents such as suspending, stabilizing and / or dispersing agents. Buffers and additives (such as saline or glucose) can be added to make the solution isotonic. For intravenous administration, the compound can also be dissolved in alcohol / propylene glycol or polyethylene glycol. These compositions can also be provided in unit dosage form in ampoules or multi-dose containers, preferably with the addition of a preservative. Alternatively, the active ingredient can be in powder form to be reconstituted with a suitable vehicle before administration.

[0037] The dosage of the compound in the composition of the present invention is appropriately selected depending on the type of disease, symptoms of the subject, age, administration method, etc. In the case of administration to humans, for example, but not limited thereto, if it is an oral agent, it is usually 10 to 5000 mg, preferably 20 to 2000 mg, more preferably 50 to 500 mg, and even more preferably 100 to 200 mg per day, once or twice a day, for several days to several weeks, and in some cases several months to one year, continuously or intermittently. In the case of administration to cats, for example, but not limited thereto, it is usually 2 to 1000 mg, preferably 10 to 100 mg, and more preferably 20 to 40 mg per day, once or twice a day, for several days to several weeks, and in some cases several months to one year, continuously or intermittently. In the case of administration to dogs, for example, but not limited thereto, it is usually sufficient to administer 2 to 1000 mg, preferably 10 to 500 mg, more preferably 20 to 100 mg per day, once or twice a day, for several days to several weeks, and in some cases, for several months to a year, continuously or intermittently. In the case of administration for the treatment of bovine protothecal mastitis, for example, but not limited thereto, it is usually sufficient to administer 10 to 10000 mg, preferably 20 to 5000 mg, more preferably 50 to 1000 mg per day, once or twice a day, for several days to several weeks, and in some cases, for several months to a year, continuously or intermittently.

[0038] The compositions of the present invention may also contain other antifungal agents in addition to ravuconazole or fosravuconazole, including, but not limited to, natamycin, rimocidin, nystatin, amphotericin B, candicin, hamycin, perimycin, miconazole, ketoconazole, clotrimazole, econazole, omoconazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, fluconazole, fosfluconazole, itraconazole, isavuconazole, posaconazole, voriconazole, terconazole, albaconazole, abafungin, terbinafen, naftifine, butenafine, amorolfine, anidulafungin, caspofungin, micafungin, ciclopirox, tolnaftate, or flucytosine. Preferred examples of the active ingredients, which are not sufficiently effective when used alone, include kanamycin (KM), gentamicin (GM), amphotericin B (AMB), and itraconazole (ITZ).Thus, the composition of the present invention contains a combination (combination drug) of two or more active ingredients including ravuconazole or a prodrug of ravuconazole (preferably fosravuconazole) as well as other antifungal agents.

[0039] The compositions of the present invention can also be administered in combination with other drugs for combination therapy. Co-administration includes sequential, simultaneous or parallel administration of the two drugs. Other drugs that can be administered in combination include the antifungal agents described above.

[0040] The present invention also includes a method for the treatment of protothecia, comprising administering a therapeutically effective amount of ravuconazole or a prodrug of ravuconazole (preferably fosravuconazole) to an animal suffering from protothecia, preferably a dog, cat, cow, or human. The present invention also includes a method for the treatment of protothecia, comprising administering to a patient in combination with other known drugs (combination). The other drugs may include the antifungal agents described above. EXAMPLES

[0041] The present invention will be specifically described below with reference to examples, but the present invention is not limited to the following examples.

[0042] Clinical and environmental isolates of Prototheca wickerhamii, Prototheca zopfii, and Prototheca blaskeae were tested for their susceptibility to ravuconazole. Example 1 Preparation of isolated strains For Prototheca wickerhamii, isolates were obtained from dogs and cats with protothecia (1 cat and 2 dog strains). For Prototheca zopfii, isolates from prototheca bovine mastitis (10 strains, genotype 2) and environmental isolates (10 strains, genotype 1) were obtained. For Prototheca blaskeae, isolates from prototheca mastitis (1 strain) were obtained. For Prototheca zopfii, the established strain of genotype 1 (SAG20063 T ) and the established strain of Genotype 2 (SAG2021 T ) were also tested for drug susceptibility. The isolates were maintained on Yeast Extract-Peptone-Dextrose Agar (YPD: 1% yeast extract, 2% peptone, 2% dextrose, 2% agar) and subjected to antifungal susceptibility testing. The susceptibility of the isolates to the antifungal agents itraconazole (ITZ, Merck KGA) and ravuconazole (RVZ, Seren Pharma) was determined using a broth microdilution assay according to the CLSI M27-A3 guidelines. The minimum inhibitory concentration (MIC) was determined after 72 hours of incubation at 32°C. The MIC was defined as the minimum concentration that induces significant inhibition of growth (approximately 50% or more inhibition). As a control, Candida parapsilosis ATCC 22019 obtained from ATCC was used to perform the MIC assay for the CLSI M27-A3 test. The MIC results for each isolate in the CLSI M27-A3 test are shown in the table below.

[0043] [Table 1]

[0044] Three clinical isolates of Prototheca wickerhamii had MICs ranging from 4 to >32 mg / L for itraconazole versus 0.03 mg / L for ravuconazole. Eleven isolates of Prototheca zopfii genotype 1 had MICs ranging from 0.25 to >32 mg / L for itraconazole versus 0.03 mg / L for ravuconazole. Eleven isolates of Prototheca zopfii genotype 2 had MICs ranging from 4 to >32 mg / L for itraconazole versus 0.03 to 0.25 mg / L for ravuconazole. One isolate of Prototheca blaskeae had an MIC of 32 mg / L for itraconazole versus 0.03 mg / L for ravuconazole. The MICs of the azoles against the control (reference) strain Candida parapsilosis ATCC 22019 were 0.125 for itraconazole and 0.03 mg / L for ravuconazole, which are within the recommended ranges described in the insert for the CLSI M27-A3 assay. These results indicate that ravuconazole is more effective (i.e., has a stronger antialgal effect) against Prototheca species than itraconazole. Ravuconazole also showed stronger activity than kanamycin (KM), gentamicin (GM), amphotericin B (AMB) and itraconazole (ITZ) against the Prototheca species Prototheca wickerhamii, Prototheca zopfii and Prototheca blaskeae. These results indicate that ravuconazole may become a first-line drug for the treatment of protothecia in humans and animals.

[0045] The above detailed description is merely illustrative of the objects and subject matter of the present invention and is not intended to limit the scope of the appended claims. Various modifications and substitutions to the described embodiments will be apparent to those skilled in the art from the teachings set forth herein without departing from the scope of the appended claims. [Industrial Applicability]

[0046] The composition containing ravuconazole provided by the present invention is useful as a therapeutic agent for protothecia.

Claims

1. A composition for the treatment or prevention of protothecia, comprising ravuconazole or a pharma- ceutically acceptable salt, hydrate or solvate thereof as an active ingredient, wherein the protothecia is protothecia caused by Prototheca wickerhamii and / or Prototheca zopfii.

2. The composition according to claim 1, which is used for the treatment or prevention of protothecia in dogs or cats.

3. The composition according to claim 1, which is used for the treatment or prevention of protothecia in cattle.

4. The composition according to claim 1, which is a pharmaceutical composition for the treatment or prevention of protothecia in humans.

5. A composition for the treatment or prevention of protothecia, comprising fosravuconazole or a pharma- ceutically acceptable salt, hydrate or solvate thereof as an active ingredient, wherein the protothecia is protothecia caused by Prototheca wickerhamii and / or Prototheca zopfii.

6. The composition described in claim 5, wherein the fosravuconazole or a pharma- ceutically acceptable salt, hydrate or solvate thereof is an L-lysine ethanol adduct of fosravuconazole.

7. 7. The composition according to claim 5 or 6, which is used for the treatment or prevention of protothecia in dogs or cats.

8. 7. The composition according to claim 5 or 6, which is used for the treatment or prevention of protothecia in cattle.

9. The composition according to claim 5 or 6, which is a pharmaceutical composition for treating or preventing protothecia in humans.

10. A method for treating protothecia, comprising administering a therapeutically effective amount of ravuconazole, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, to an animal (excluding humans) suffering from protothecia, wherein the protothecia is protothecia caused by Prototheca wickerhamii and / or Prototheca zopfii.

11. The method of claim 10, wherein the animal is a dog or a cat.

12. The method of claim 10, wherein the animal is a cow.

13. 1. A method for treating protothecia, comprising administering to an animal (excluding humans) suffering from protothecia a therapeutically effective amount of fosravuconazole, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, wherein the protothecia is protothecia caused by Prototheca wickerhamii and / or Prototheca zopfii.

14. The method of claim 13, wherein the fosravuconazole or a pharma- ceutically acceptable salt, hydrate or solvate thereof is an L-lysine ethanol adduct of fosravuconazole.

15. 15. The method of claim 13 or 14, wherein the animal is a dog or a cat.

16. 15. The method of claim 13 or 14, wherein the animal is a cow.